INVESTORS & MEDIA

News Release

July 8, 2015 at 9:30 AM EDT

Regeneron to Report Second Quarter 2015 Financial and Operating Results and Host Conference Call and Webcast on August 4, 2015

TARRYTOWN, N.Y., July 8, 2015 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2015 financial and operating results on Tuesday, August 4, 2015, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.

Conference Call Information
To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International).  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at www.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days. 

About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron commercializes medicines for eye diseases and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, asthma, and atopic dermatitis.  For additional information about the company, please visit www.regeneron.com.

Contact Information:




Investor Relations                                

Corporate Communications

Manisha Narasimhan, Ph.D.                     

Hala Mirza

914.847.5126                                          

914.847.3422             

manisha.narasimhan@regeneron.com   

hala.mirza@regeneron.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regeneron-to-report-second-quarter-2015-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-4-2015-300109702.html

SOURCE Regeneron Pharmaceuticals, Inc.

News Provided by Acquire Media